Cenerimod is under clinical development by Idorsia Pharmaceutical and currently in Phase III for Systemic Lupus Erythematosus. According to GlobalData, Phase III drugs for Systemic Lupus Erythematosus have a 29% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Cenerimod’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cenerimod overview
Cenerimod (ACT-334441) is under development for the treatment of systemic lupus erythematosus. It is a small molecule administered through oral route in the form of film-coated tablet. It acts by targeting sphingosine-1-phosphate receptor 1 (S1P1).
The drug candidate was also under development for the treatment of sicca syndrome (Sjogren).
Idorsia Pharmaceutical overview
Idorsia Pharmaceutical (Idorsia), a subsidiary of Idorsia Ltd, is a biopharmaceutical company. It discovers, develops, and commercializes therapies to treat central nervous system (CNS), cardiovascular, immunological disorders, and orphan diseases. The company’s product portfolio includes Quviviq, a daridorexant, to treat insomnia; Pivlaz, a clazosentan, for the treatment of cerebral vasospasm; and Tryvio, an aprocitentan, for the treatment of uncontrolled hypertension. Idorsia’s pipeline includes various drugs for the treatment of fabry disease, pediatric insomnia, demyelinating diseases, rare lysosomal storage disorders, recent-onset type 1diabetes, immune-mediated disorders, and clostridium difficile infection. The company has a vaccine platform for the development of glycoconjugate vaccines containing synthetic antigenic glycan molecules to prevent infection. It has a presence in Japan, the UK, South Korea, Switzerland, and the US. Idorsia is headquartered in Arlesheim, Basel-Landschaft, Switzerland.
For a complete picture of Cenerimod’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
